VLA1553 Chikungunya Vaccine Maintains 94.5% Seroresponse at 4 Years
Trial Shows VLA1553 Vaccine Maintains Protection Against Chikungunya Virus
In a single-arm observational extension of a phase 3b trial, 240 of 254 adults who received a single dose of VLA1553 had seroresponse at 4 y…
A single-dose vaccine shows high antibody levels against Chikungunya for at least four years, including in adults over age 65.
VLA1553 vaccination induces sustained neutralizing antibodies in Brazilian adolescents against chikungunya virus
A New Shield for Teens Against Chikungunya
This randomized, placebo-controlled phase 3 trial evaluated the single-dose VLA1553 vaccine in 754 generally healthy adolescents aged 12 to …
This vaccine gives teenagers strong protection against chikungunya fever without causing serious harm.